Clinical Trials
105 trialsNCT04513925 2026-06-03
SKYSCRAPER-03
Hoffmann-La Roche
Phase 3 Completed
NCT04619797 2026-06-03
SKYSCRAPER-06
Hoffmann-La Roche
Phase 2/3 Completed
NCT04042558 2026-05-12
GFPC 06-2018
Centre Francois Baclesse
Phase 2 Completed
NCT04665843 2026-05-05
SKYSCRAPER-09
Hoffmann-La Roche
Phase 2 Completed
NCT03563716 2026-05-04
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Genentech, Inc.
Phase 2 Completed
NCT03483012 2026-04-21
Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03694262 2026-04-13
EndoBARR
Medical College of Wisconsin
Phase 2 Completed
NCT04540211 2026-04-09
SKYSCRAPER-08
Hoffmann-La Roche
Phase 3 Completed
NCT04256421 2026-04-03
SKYSCRAPER-02
Hoffmann-La Roche
Phase 3 Completed
NCT04300647 2026-03-12
SKYSCRAPER-04
Hoffmann-La Roche
Phase 2 Completed
NCT02530489 2026-02-17
Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04148911 2025-12-26
EL1SSAR
Hoffmann-La Roche
Phase 3 Completed
NCT04471428 2025-12-22
CONTACT-01
Hoffmann-La Roche
Phase 3 Completed
NCT04862949 2025-12-12
Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC
CHA University
Completed
NCT05171777 2025-12-11
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT03735121 2025-12-05
A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT03193190 2025-11-21
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT03371017 2025-11-12
IMpassion132
Hoffmann-La Roche
Phase 3 Completed
NCT03738228 2025-11-12
Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT03280563 2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2 Completed
NCT04631029 2025-10-03
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
National Cancer Institute (NCI)
Phase 1 Completed
NCT03041311 2025-09-25
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
G1 Therapeutics, Inc.
Phase 2 Completed
NCT04487067 2025-09-22
AMETHISTA
Hoffmann-La Roche
Phase 3 Completed
NCT05459129 2025-09-15
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT03977467 2025-08-27
Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02908672 2025-07-20
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
Hoffmann-La Roche
Phase 3 Completed
NCT05116202 2025-07-18
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
Hoffmann-La Roche
Phase 1/2 Completed
NCT04477759 2025-07-15
DEHART
Medical College of Wisconsin
Phase 1 Completed
NCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT03108131 2025-05-28
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02844816 2025-05-22
Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT04602078 2025-04-24
AUREA
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT03473756 2025-04-09
FORT-2
Bayer
Phase 1 Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT02807636 2025-02-24
IMvigor130
Hoffmann-La Roche
Phase 3 Completed
NCT02724878 2025-02-13
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03285763 2025-01-23
TAIL
Hoffmann-La Roche
Phase 4 Completed
NCT04632992 2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2 Completed
NCT03206203 2024-12-12
Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT02708680 2024-12-04
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Syndax Pharmaceuticals
Phase 1/2 Completed
NCT03730012 2024-11-29
A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
Astellas Pharma Inc
Phase 1/2 Completed
NCT03726879 2024-11-05
IMpassion050
Hoffmann-La Roche
Phase 3 Completed
NCT03800836 2024-10-30
A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT04091217 2024-10-24
Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
Hoffmann-La Roche
Phase 2 Completed
NCT03191786 2024-10-23
IPSOS
Hoffmann-La Roche
Phase 3 Completed
NCT03526900 2024-10-09
ATEZO-BRAIN
Spanish Lung Cancer Group
Phase 2 Completed
NCT02927301 2024-09-19
A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)
Genentech, Inc.
Phase 2 Completed
NCT04123470 2024-09-19
A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma
Lokon Pharma AB
Phase 1/2 Completed
NCT02873195 2024-08-23
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Completed